IL17A and laryngotracheoesophageal cleft: Mechanically, IL-35 could prevent the binding of TGF-β and its receptor, which inhibit phosphorylation of Smad3 a downstream effector of TGF-β receptor, thereby preventing the differentiation of Th17 cells and the synthesis of IL-17 in the blood of HBV-related LC patients (Ming et al., 2015).